Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185)

Hong Kong · Delayed Price · Currency is HKD

0.9800

+0.0500 (5.38%)

Nov 2, 2026, 3:48 PM HKT

Market Cap	238.55M -88.2%
Revenue (ttm)	44.39M +84.3%
Net Income	-87.16M
EPS	-0.36
Shares Out	243.42M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	133,100
Open	0.9900
Previous Close	0.9300
Day's Range	0.9700 - 0.9950
52-Week Range	0.9300 - 8.8000
Beta	0.14
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About HKG:2185

Shanghai Bio-heart Biological Technology Co., Ltd., together with its subsidiaries, engages in the research, development, and commercialization of invasive treatment products in China. The company develops Bioheart, a bioresorbable scaffolds system, which is in registration stage for percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis, a renal denervation system, which is in clinical stage for the treatment of uncontrolled hypertension and resistant hypertension; and DCB, a sirolimus drug coated ba... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2014

Employees 63

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2185

Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements